Clinical
Features |
Pneumonia, bacteremia, otitis media,
meningitis, sinusitis, peritonitis and arthritis. |
Etiologic
Agent |
Streptococcus pneumoniae.
More than 90 serotypes exist; of strains causing invasive
disease, 88% are serotypes included in the 23-valent polysaccharide
vaccine. Before the new pneumococcal conjugate vaccine was
introduced in 2001, over 80% of invasive isolates in children
<5 years old were included in the 7-valent vaccine. |
Incidence |
Until 2000, S. pneumoniae infections caused 100,000-135,000
hospitalizations for pneumonia, 6 million cases of otitis
media, and 60,000 cases of invasive disease, including 3300
cases of meningitis. Incidence of sterile-site infections
showed geographic variation from 21 to 33 cases per 100,000
population. Disease figures are now changing due to conjugate
vaccine introduction.; in 2002, the rate of invasive disease
was 13 cases per 100,000 in the United States.
|
Sequelae |
Death occurs in 14% of hospitalized
adults with invasive disease. Neurologic sequelae and/or learning
disabilities can occur in meningitis patients. Hearing impairment
can result from recurrent otitis media. |
Transmission |
Person to person. |
Risk
Groups |
Persons at higher risk for infection
are the elderly, children under 2 years old, blacks, American
Indians and Alaska Natives, children who attend group day
care centers, and persons with underlying medical conditions
including HIV infection and sickle-cell disease. |
Surveillance |
Active, population-based surveillance
is conducted in nine states (total population: 25 million).
Reporting of drug-resistant S. pneumoniae and all invasive
disease in children <5 years old has been mandated in several
states. A nationwide system tracks invasive disease occurring
in children <5 years who have been vaccinated. |
Trends |
The incidence among young adults
and young children is decreasing, due to improved HIV therapy
and to use of the new conjugate vaccine for children. Outbreaks
have occurred in institutional settings and child care centers.
In the United States, ß-lactam resistance is common
and prevalence of strains resistant to multiple classes of
drugs is increasing. |
Challenges |
Supplies of pneumococcal conjugate
vaccine are inadequate. The 23-valent polysaccharide vaccine
is underused. Sensitive, rapid diagnostic tests are not available
for many types of pneumococcal infections, although a new
urinary antigen test may be useful in adults. Widespread overuse
of antibiotics contributes to emerging drug resistance. |
Opportunities |
Ability to prevent infections could
improve through expanded use of 23-valent polysaccharide vaccine
among adults and through use of the conjugate vaccine for
infants and young children. Campaigns for judicious use of
antibiotics along with the new vaccine may slow or reverse
emerging drug resistance. |
|
December 2003
|